Innovating Clinical Research with AI and Real World Data

The development of new medicines remains a lengthy, costly, and high-risk process. AI and Real World Data (RWD) offer opportunities to address key challenges across the drug development lifecycle - from preclinical research to market authorization and beyond. Applied effectively, they can improve clinical trial design, and enable more patient-centric approaches. Using digital twins as a concrete example, this session highlights how AI and RWD can contribute to better outcomes and outlines what is needed to increase their impact for patients.